Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96

Affiliations

¹ Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@gsuro.com.
² The Institute of Cancer Research and Royal Marsden Hospital, London, UK.
³ Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels, Belgium.

Comment

Neal D Shore et al. Eur Urol. 2020 Nov.

. 2020 Nov;78(5):e196-e197.

doi: 10.1016/j.eururo.2020.07.034. Epub 2020 Aug 21.

¹ Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@gsuro.com.
² The Institute of Cancer Research and Royal Marsden Hospital, London, UK.
³ Service d'Urologie, Cliniques Universitaires Saint Luc, Brussels, Belgium.

No abstract available

Comment on

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
Mahal BA, D'Amico AV, Nguyen PL. Mahal BA, et al. Eur Urol. 2020 Nov;78(5):e195. doi: 10.1016/j.eururo.2020.07.030. Epub 2020 Aug 28. Eur Urol. 2020. PMID: 32863056 No abstract available.